Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-9539 injection and HRS-3738 tablets, indicating progress in their drug development pipeline [1] Group 1: Clinical Trial Approval - Jiangsu Heng Rui Medicine Co., Ltd. and its subsidiaries have been granted the Clinical Trial Approval Notice for SHR-9539 injection and HRS-3738 tablets [1] - The approval is based on the review under the Drug Administration Law of the People's Republic of China, confirming that the drugs meet the registration requirements [1] - The specific study involves a Phase I/II trial of SHR-9539 in combination therapy for multiple myeloma [1]

Group 1 - The core point of the article is that Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-2906 injection, which will soon commence [1][2] Group 2 - Drug Name: SHR-2906 Injection [2] - Dosage Form: Injection [2] - Application Matter: Clinical Trial [2] - Acceptance Number: CXSL2500799 [2] - Approval Conclusion: The clinical trial application for SHR-2906 injection, accepted on September 17, 2025, meets the requirements for drug registration and is approved to conduct clinical trials for overweight or obesity [2]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of several new drug candidates, indicating a significant advancement in its oncology pipeline and potential market opportunities in the pharmaceutical industry [1][2]. Group 1: Drug Candidates - HRS-6208 is a novel, selective small molecule inhibitor that effectively suppresses phosphorylation activation of its target, impacting cell cycle and transcriptional activity to inhibit tumor cell proliferation. No similar products have been approved in the market to date. The cumulative R&D investment for HRS-6208 is approximately 38.14 million yuan [1]. - HRS-6209 is a selective CDK4 inhibitor that induces tumor cell arrest in the G1 phase, aimed at treating advanced malignant solid tumors. It shows improved selectivity over CDK6/cyclinD3 signaling compared to existing CDK4/6 inhibitors, potentially reducing hematologic toxicity. The cumulative R&D investment for HRS-6209 is approximately 119.85 million yuan [1]. - HRS-8080 is a novel, selective oral estrogen receptor degrader (SERD) designed to treat ER-positive and ER-mutated breast cancer. The cumulative R&D investment for HRS-8080 is approximately 198.70 million yuan [2]. - HRS-5041 is a new, selective AR PROTAC small molecule aimed at treating prostate cancer, showing significant degradation of wild-type and most mutant AR proteins, with potential to overcome resistance compared to second-generation AR inhibitors. The cumulative R&D investment for HRS-5041 is approximately 92.66 million yuan [2]. - HRS-1358 is a targeted estrogen receptor (ER) degrading PROTAC molecule that can effectively degrade ER and inhibit its transcriptional activity, with the potential to overcome resistance due to target protein mutations. The cumulative R&D investment for HRS-1358 is approximately 96.01 million yuan [2].

Core Viewpoint - The company, Heng Rui Medicine, has received approval from the National Medical Products Administration for clinical trials of five new drug candidates, indicating a significant advancement in its oncology pipeline [1][2][3]. Group 1: Drug Candidates Overview - HRS-6208 is a novel, highly selective small molecule inhibitor that effectively suppresses phosphorylation activation of its target, impacting cell cycle and transcriptional activity to inhibit tumor cell proliferation. No similar products have been approved in the market, with a cumulative R&D investment of approximately 38.14 million yuan [1]. - HRS-6209 is a selective CDK4 inhibitor that induces tumor cell arrest in the G1 phase, aimed at treating advanced malignant solid tumors. It shows improved selectivity over CDK6/cyclinD3 pathways compared to existing CDK4/6 inhibitors, with a cumulative R&D investment of about 119.85 million yuan [2]. - HRS-8080 is a novel oral selective estrogen receptor degrader (SERD) designed to degrade ER and inhibit its activity, targeting ER-positive and ER-mutated breast cancer. The cumulative R&D investment for this project is around 198.70 million yuan [2]. - HRS-5041 is a new, highly selective AR PROTAC molecule intended for prostate cancer treatment, demonstrating significant degradation of wild-type and most mutant AR proteins, with a cumulative R&D investment of approximately 92.66 million yuan [3]. - HRS-1358 is a targeted estrogen receptor (ER) degrading PROTAC molecule that can overcome resistance due to target protein mutations, with a cumulative R&D investment of about 96.01 million yuan [3].

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of its injectable Leuprolide Acetate Microspheres, targeting prostate cancer treatment [1] Drug Information - Drug Name: Injectable Leuprolide Acetate Microspheres [1] - Dosage Form: Injectable [1] - Application Matter: Clinical Trial [1] - Acceptance Number: CYHL2500159 [1] - Approval Conclusion: The clinical trial application for Injectable Leuprolide Acetate Microspheres, accepted on August 29, 2025, meets the requirements for drug registration and is approved to conduct clinical trials for prostate cancer [1]

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of injectable acetic acid leuprolide microspheres, which will be conducted soon [1] Group 1: Product Information - Acetic acid leuprolide is a GnRH analog used for the treatment of prostate cancer [1] - The original research product LEUPLIN Pro was developed by Takeda Pharmaceutical Company and was approved for market in Japan in November 2015, but has not yet been launched in China [1] - The dosage and administration of the injectable acetic acid leuprolide microspheres differ from the already marketed injectable leuprolide microspheres in China, making it a generic version of an overseas product that is not yet available domestically [1] Group 2: Financial Investment - The cumulative R&D investment for the injectable acetic acid leuprolide microspheres project has reached approximately 24.68 million yuan [1]

Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for clinical trials of injectable acetic acid leuprolide microspheres, which will be conducted shortly [1] Group 1: Product Information - Acetic acid leuprolide is a GnRH analog used for the treatment of prostate cancer [1] - The original research product LEUPLIN®Pro was developed by Takeda Pharmaceutical Company and was approved for market in Japan in November 2015, but has not yet been launched domestically [1] - The dosage and administration of the injectable acetic acid leuprolide microspheres differ from the already marketed injectable leuprolide microspheres in China, making it a generic version of an overseas product that has not been launched domestically [1] Group 2: Financial Investment - The total research and development investment for the injectable acetic acid leuprolide microspheres project has reached approximately 24.68 million yuan [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of its injectable leuprolide acetate microspheres for prostate cancer treatment [1] Group 1: Company Announcement - Heng Rui Medicine's subsidiary, Shanghai Heng Rui Medicine Co., Ltd., has been granted a clinical trial approval notice for leuprolide acetate microspheres [1] - The drug is a GnRH analog intended for the treatment of prostate cancer [1] - The original product, LEUPLIN Pro, was developed by Takeda Pharmaceutical Company and was approved for market in Japan in November 2015, but has not yet been launched in China [1] Group 2: Product Details - The formulation and dosage of leuprolide acetate microspheres differ from the already marketed injectable leuprolide in China [1] - The product is classified as a generic version of an overseas drug that has been approved but not yet launched domestically [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-2906 injection, aimed at treating overweight or obesity [1] Group 1: Product Development - SHR-2906 injection is a self-developed biological product by Heng Rui Medicine, expected to have a synergistic effect in reducing energy intake and promoting energy expenditure, thereby regulating glucose and lipid metabolism and controlling weight [1] - The product aims to improve the metabolic environment within the body, potentially demonstrating clinical efficacy in treating overweight and obesity [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of SHR-2906 injection, a self-developed therapeutic biological product aimed at regulating glucose and lipid metabolism and controlling weight [1] Group 1: Product Development - SHR-2906 injection is expected to synergistically reduce energy intake and promote energy expenditure, improving the metabolic environment in the body and potentially offering clinical efficacy in treating overweight and obesity [1] - There are currently no similar drugs approved for market use domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]